Orforglipron vs Oral Semaglutide Pill: What the ACHIEVE-3 Trial Actually Showed
In the head-to-head ACHIEVE-3 trial, oral orforglipron (Foundayo) beat the oral semaglutide pill on blood sugar and weight loss in type 2 diabetes — but with more GI side effects, double the dropout rate, and no cardiovascular indication yet. Here’s what that tradeoff actually means.
Orforglipron vs Oral Semaglutide Pill: What the ACHIEVE-3 Trial Actually Showed Read More »
